Oncology Medical News about Thyroid Cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The utility of radioiodine scans prior to ¹³¹I ablation in patients with well-differentiated thyroid cancer
Thyroid, 03/23/09

Nostrand DV et al. - Pre-ablation radioiodine (RAI) scans demonstrate a significant number of findings that may alter the management of patients with well-differentiated thyroid cancer prior to ¹³¹I ablation.

Methods

Study to evaluate the utility of RAI scans prior to ¹³¹I ablation in pts with well-differentiated thyroid cancer
All RAI scans performed were reviewed
Pts excluded who were suspected of having:

loco-regional disease
distant metastases
and/or physiological uptake

RAI scans performed either 24h or 48h after dosing with 37–148 MBq of ¹³¹I
One reviewer blindly evaluated each set of scans using 6 criteria:

No. of foci of RAI uptake in thyroid bed/neck
Location(s) of these foci
Size of the largest foci
Percent uptake
Uptake suggestive of distant metastases
Significant altered biodistribution

Results

53% of pts had findings on the RAI scans that might have altered the pt's management prior to their ¹³¹I ablation
The data grouped by the criteria noted above were:
- 12% with ≥6 foci suggesting local metastases and 6% with no focal uptake
- 14% with suggestion of lymph node metastases
- 1.1% with ≥1 focus lobe
- 8% with ≥15% uptake
- 4% with distant metastases
- 16% demonstrating altered distribution with 6% breast, 3% salivary, 10% GI, and 0.3% urinary bladder

<< Previous
Derivation of molecular signatures for breast cancer recurrence...

Next >>
Adjuvant imatinib mesylate after resection of localised, primary...